{"links":{"html":"https://www.erudio.com/reports/her2-cr-nct06663787","json":"https://www.erudio.com/reports/her2-cr-nct06663787.json","markdown":"https://www.erudio.com/reports/her2-cr-nct06663787.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"her2-cr-06663787"}},"request":"https://www.erudio.com/contact?report=her2-cr-06663787"},"offer":{"cited_commentary_sources":10,"verified_hcp_statements":37,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":8,"optional":true,"price_per_verified_person_usd":15,"price_usd":120,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"her2-cr-nct06663787"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=her2-cr-06663787","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/her2-cr-nct06663787","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T15:30:19.840763Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":0},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: The status of ctDNA"},{"claim_count":4,"coverage":"discussed","id":"T2","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T3","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":4,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.interventions","source_count":3,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":2,"title":"Ultrasensitive testing and the meaning of ctDNA negativity"},{"claim_count":8,"coverage":"discussed","id":"A2","source_count":1,"title":"Routine monitoring, imaging and patient support"},{"claim_count":7,"coverage":"discussed","id":"A3","source_count":2,"title":"Continued maintenance versus chemotherapy withdrawal"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":2,"title":"Stop HER2 and the separate treatment-break research question"}],"counts":{"cited_sources":11,"claims_by_expression_type":{"comparison":1,"experience":3,"interpretation":8,"opinion":11,"primary_context":3,"question":1,"restatement":7,"uncertainty":2,"unspecified":1},"claims_by_kind":{"limitation":1,"protocol_statement":1,"source_observation":35},"clinician_statements":23,"evidence_units":27,"findings":5,"organisational_accounts":1,"people_cited":9,"people_identity_verified":8,"people_total":11,"screened_sources":13,"verified_claims":37},"findings_index":[{"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":6,"views":7},"has_counterview":false,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":6,"passages":9,"sources":9,"sources_by_kind":{"commentary":7,"media":1,"registry":1}},"title":"Enthusiasm supports testing treatment cessation, not declaring it safe"},{"id":"F2","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"Assay sensitivity changes the meaning of a negative result"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":6},"has_counterview":false,"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":2,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"Where does ctDNA response monitoring fit alongside imaging?"},{"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":3,"questions":1,"restated":2,"views":1},"has_counterview":false,"limitations":4,"links":{"context":1,"support":7},"ma_question":true,"named_voices":2,"passages":6,"sources":2,"sources_by_kind":{"media":2}},"title":"Chemotherapy withdrawal is not the same decision as stopping anti-HER2 maintenance"},{"id":"F5","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"Stop HER2 addresses a separate, explicit treatment-break question"}],"medical_affairs_question":"What assay definition, serial-response criteria and prospective safety evidence would justify a treatment break without displacing imaging or confusing chemotherapy withdrawal with anti-HER2 cessation?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Can ctDNA guide safe anti-HER2 treatment discontinuation?"},{"id":"section-2","level":2,"title":"Assay sensitivity determines what negativity can distinguish"},{"id":"section-3","level":2,"title":"Investigational response monitoring does not displace imaging or patient support"},{"id":"section-4","level":2,"title":"Maintenance continuation, chemotherapy withdrawal and complete cessation are different choices"},{"id":"section-5","level":2,"title":"Stop HER2 keeps the actual treatment-break question distinct"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"observational, cohort, prospective","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4}],"id":"T1","label":"Primary endpoint: The status of ctDNA"},{"findings":[{"id":"F1","shared_claims":4}],"id":"T2","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F5","shared_claims":1}],"id":"T3","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":2}],"id":"T4","label":"Safety and tolerability"}]},"identity":{"accepted_at":"2026-11-01T15:30:19.840763Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T15:40:46Z","record_hash":"4d0ed4c52cb8eee2d3ced0d8dafac323c103c90800093de171cf234120d1739f","release_hash":"7fc98ec6e6682b5c8613d78e0681571e9fcb8e12a181583b6abb29ef3ef301c4","report_id":"erudio-nct06663787","run_id":"31f57116-0403-4cbb-889d-9060d75d5307","schema_version":"5.0","slug":"her2-cr-06663787","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"HER2 CR assesses circulating tumor DNA (ctDNA) status in durable responders with HER2-positive metastatic breast cancer; the discussion distinguishes investigating anti-HER2 cessation from establishing safety. The report cites six physicians, five of them medical oncologists, and examines assay sensitivity and ctDNA monitoring alongside imaging. What assay definitions, serial-response criteria and prospective safety evidence would justify treatment breaks without replacing imaging or confusing chemotherapy withdrawal with anti-HER2 cessation? The sources place HER2-CR’s initial results at ESMO 2026.","meta_description":"13 sources screened · 37 verified statements (23 from clinicians verified by NPI or staff page) from 11 sources · 5 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-6cbad300d48ee0e5648c","claim-c67a866d0461bab8b16b"],"id":"F1","paraphrase":"An X post by a medical oncologist addressed the questions of ctDNA-guided de-escalation research and treatment-discontinuation safety in relation to HER2 CR.","publication_caveats":["The full HER2-CR results article and a separate protocol were not available in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":"2026-10-26","title":"Enthusiasm supports testing treatment cessation, not declaring it safe"}]},"publication":{"approved_at":"2026-11-01T15:40:46Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":13},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","Commentary on ctDNA status and subsequent outcomes, limitations of conventional disease assessment, and the evidence needed to establish clinical utility is not fully covered. This report should not be used to infer that those views were absent from the sources.","The full HER2-CR results article and a separate protocol were not available. Reported numerical findings are attributed summaries rather than an independently assessed full results report; registry material describes planned assessments.","Drug-label material was unavailable. The adverse-effect comments should be read as a speaker's regimen description, not a comprehensive safety assessment or a comparison of stopping versus continuing treatment.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","No individual is identified for the BC Tube statements. Presentation relays, reposts and repeated quoted posts should not be counted as additional independent clinical opinions.","The broader recordings discuss related monitoring and treatment-duration questions, including separate datasets and Stop HER2. Their findings, eligibility descriptions and expected reporting timelines must not be transferred to HER2-CR, and different source dates do not establish a change of mind.","The treatment-continuation examples are not a complete account of maintenance alternatives or decisions after focal progression."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":7,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":10,"methods":1},"count":11,"evidence_window":{"end":"2026-10-26","start":"2025-10-16"},"retrieval_snapshot":"2026-11-01T14:46:22.303608Z","timeline":[{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":7,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06663787:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06663787:context","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114019278563537244:ae7ce6eb-fccc-4bc2-850c-788fba8c519b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114665720185282766:afd9e0f6-2ec9-4715-a2bf-f72ff87fc384","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114666233018601723:a53690e2-4d2a-4537-8b60-f0e883cb3d23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114666389474586744:4b1be82e-4aaf-4e8f-b544-26a82bb2f2b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114667367322230788:7ff2c188-e63f-461e-befd-52996e3794a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114667412650095100:9c135cd8-afaf-4a03-9436-7c4c179060a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114676670426738863:b3796bff-0d1b-490b-ae22-7863fd8f8d5d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114676678962336141:63f85774-2b07-4bb5-b612-07cad3b34b49","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114715988373750199:252650e4-bea0-4b1f-9a8d-1a5e0a01e5ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115390155427287417:bc4a7fcc-f81a-4076-93c2-06b28e70f8fa","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:CyRcgkN0KgY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:alZvkdAQbPc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:igXjKgLRXW8","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":10,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":13},"count":13,"evidence_window":{"end":"2026-10-28","start":"2025-10-16"},"retrieval_snapshot":"2026-11-01T14:46:22.303608Z","timeline":[{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":9,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Herceptin"],"label":"trastuzumab","slug":"trastuzumab"}],"indications":[{"reason":"Unmapped registry condition: Breast Cancer, Metastatic","status":"unmapped"},{"reason":"Unmapped registry condition: HER2 + Breast Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"HER2 CR","aliases":["HER2 CR","Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment","Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment"],"brief_title":"Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Breast Cancer, Metastatic","HER2 + Breast Cancer"],"enrollment":{"count":50,"type":"ESTIMATED"},"interventions":[{"name":"Trastuzumab (Herceptin)","synonyms":["Trastuzumab Emtansine","Trastuzumab Deruxtecan"],"type":"DRUG"},{"name":"SIgnatera","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DIAGNOSTIC_TEST"}],"nct_id":"NCT06663787","official_title":"Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment","overall_status":"ACTIVE_NOT_RECRUITING","phase":{"reason":"Observational study; registry phases do not apply.","status":"not_applicable"},"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"To assess the status of ctDNA in CR patients with/without continuing treatment, or PR patients with continuing treatment","measure":"The status of ctDNA","timeFrame":"1 year"}],"registered_date":{"date":"2024-10-29","type":"ACTUAL"},"registry_last_updated":"2026-05-13","registry_url":"https://clinicaltrials.gov/study/NCT06663787","short_name":"HER2 CR","short_name_basis":"registry_acronym","sponsor":"Nagoya City University","start_date":{"date":"2024-04-01","type":"ACTUAL"},"study_design":"observational, cohort, prospective","study_ids":[{"id":"HER2 CR","type":"sponsor_study_id"},{"domain":"Nagoya City Unversity","id":"80-24-0057","type":"other"}],"study_type":"OBSERVATIONAL"}}}